PAVmed Inc.

PAVmed Inc. reported a net loss attributable to common stockholders of $12.47 million for the six months ended June 30, 2026, a significant decline from a $4.39 million net income in the prior year. The company's management raised substantial doubt about its ability to continue as a going concern due to recurring losses and negative operating cash flows. Despite increased revenue to $55,000, operating expenses also rose, leading to an increased operating loss, though financing activities provided $7.56 million in cash.

PAVmed Inc. held its Annual Meeting of Stockholders on June 24, 2026, with approximately 59.6% of shares represented. Stockholders re-elected Ronald M. Sparks and Timothy Baxter as Class A directors. They also approved amendments to the Employee Stock Purchase Plan (ESPP), increasing the total shares available by 200,000 to 215,774 and raising the annual evergreen limit to 500,000 shares. Additionally, the appointment of CBIZ CPAs P.C. as the independent registered certified public accounting firm for 2026 was ratified.

PAVmed Inc. announced its first quarter 2026 financial results, reporting a GAAP net loss of $7.0 million, or $(4.42) per diluted common share. Despite the loss, the company provided positive business updates across its subsidiaries. Lucid Diagnostics generated $1.3 million in EsoGuard revenue and significantly strengthened its balance sheet with a $17 million public offering, boosting proforma cash to $45 million and extending its runway into 2027. Veris Health advanced its implantable physiological monitor towards FDA submission and expanded commercial engagement, while PAVmed relaunched its medical device portfolio.

PAVmed Inc. reported a net loss attributable to common stockholders of $(6.99) million for Q1 2026, a significant decline from a net income of $17.70 million in Q1 2025. The company's operating loss also increased to $(8.04) million. Management raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows from operations. The company secured $29.91 million from Series D Preferred Stock and $15.0 million from a Senior Secured Convertible Note to support operations.

PAVmed Inc. announced its Annual Meeting of Stockholders to be held virtually on June 24, 2026. Key proposals include the re-election of two Class A directors, the ratification of CBIZ CPAs P.C. as the independent auditor for 2026, and significant amendments to the Employee Stock Purchase Plan (ESPP). The ESPP amendments propose to increase the total shares available by 200,000 to 215,774 and raise the annual evergreen provision limit from 5,556 to 500,000 shares.